Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.1
4.3
Journals
Pharmaceuticals
Special Issues
Recent Advances in Drug Metabolism, Transport, and Pharmacokinetics
share announcement

Recent Advances in Drug Metabolism, Transport, and Pharmacokinetics

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".

Deadline for manuscript submissions: 30 September 2025 | Viewed by 4001

Special Issue Editors

Prof. Dr. Agnieszka Bienert

E-Mail Website
Guest Editor
Department of Clinical Pharmacy and Biopharmacy, Poznan University of Medical Sciences, Poznan, Poland
Interests: pharmacodynamics and pharmacokinetics; molecular and clinical pharmacology; pharmacogenetics; PKPD modeling; clinical PKPD studies; clinical pharmacy
Dr. Joanna Bartkowiak-Wieczorek

E-Mail Website
Guest Editor
Department of Physiology, Poznan University of Medical Sciences, 61-701 Poznan, Poland
Interests: nutritional biochemistry; gynaecology; clinical pharmacology; genetics; pharmacogenetics; osteoporosis; bone; bone mineral density; genotyping; bone metabolism
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Medicines approved for use must demonstrate effectiveness and safety. Every drug must be evaluated based on a statistical analysis of clinical studies performed in patient populations. However, in later clinical practice, the percentage of patients responding to the therapy is much lower than what we wished for. The pharmacological response to the drug, including its side effects, is strongly related to its concentration in the target tissue and other organs. The principles of the concentration–effect relationship are the basis of pharmacodynamics (PD), whereas pharmacokinetics (PK) studies the effect of an organism on a drug and describes the time course of drug concentration. Currently, pharmacotherapy favors personalization. We realize that the inter- and intra-individual variability in the clinical response to a drug is high and that many factors contribute to this. Determining the mechanism and kinetics of different processes that the drug undergoes in the body and the factors limiting these processes is challenging. To overcome this challenge, we need advances in the scientific processes related to drug pharmacokinetics to predict the drug disposition in every patient. This Special Issue focuses on this topic.   We welcome original research articles, reviews, meta-analyses, and other publication types in this Special Issue titled “Recent Advances in Drug Metabolism, Transport, and Pharmacokinetics”. We are particularly interested in innovative studies that explore new insights and developments in drug metabolism, transport mechanisms, and pharmacokinetic modeling and contributions that address the challenges and opportunities in personalizing pharmacotherapy. This Special Issue will contribute to a deeper understanding of these critical areas and help shape the future of individualized treatment strategies.

Prof. Dr. Agnieszka Bienert
Dr. Joanna Bartkowiak-Wieczorek
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • pharmacokinetic analysis
  • analytical methods suitable for pharmacokinetics studies
  • pharmacogenetics in drug pharmacokinetics
  • clinical pharmacokinetics
  • drug concentrations in plasma and tissue
  • population PK modeling
  • drug metabolic pathways
  • drug transport across barriers

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

18 pages, 9548 KiB  
Article
The Application of the Design of Experiments and Artificial Neural Networks in the Development of a Fast and Straightforward HPLC-UV Method for Fluconazole Determination in Hemato-Oncologic Pediatric Patients and Its Adaptation to Therapeutic Drug Monitoring
by Arkadiusz Adamiszak, Andrzej Czyrski, Bartosz Sznek, Edmund Grześkowiak and Agnieszka Bienert
Pharmaceuticals 2024, 17(12), 1679; https://doi.org/10.3390/ph17121679 - 12 Dec 2024
Cited by 1 | Viewed by 1048
Abstract
Objectives: This study aimed to develop an optimized and wide concentration range HPLC-UV method for fluconazole (FLU) determination and its adaptation for pharmacokinetics (PK) studies in the pediatric population. Methods: The following parameters of chromatographic separation were optimized: retention time, tailing factor, peak [...] Read more.
Objectives: This study aimed to develop an optimized and wide concentration range HPLC-UV method for fluconazole (FLU) determination and its adaptation for pharmacokinetics (PK) studies in the pediatric population. Methods: The following parameters of chromatographic separation were optimized: retention time, tailing factor, peak height, and the sample preconditioning parameter, such as recovery. The optimization process involved the use of a central composite design (CCD) and Box–Behnken design (BBD) in the design of experiments (DoE) approach and a multilayer perceptron (MLP) for artificial neural network (ANN) application. Statistical and PK analyses were performed using Statistica and PKanalix. Results: The acetonitrile (ACN) concentration revealed the most significant factor influencing the retention time, tailing factor, and peak height of FLU and the internal standard. For recovery, the extracting agent’s volume was the most significant factor. In most cases, the analysis conducted with the DoE and ANN indicated the same factors in a similar order regarding their impact on the analyzed variables. The optimization process allowed for achieving a wide range of determined concentrations (0.5–100 mg/L) and ~100% recovery. The developed method enabled PK analysis of 12 samples from three pediatric patients, proving its clinical usability. The estimated median clearance (CL) and volume of distribution (Vd) were 1.01 L/h and 18.64 L, respectively. Conclusions: DoE and ANNs are promising and useful tools in the optimization of sample preconditioning as well as the HPLC separation procedure. The investigated fluconazole determination method meets the European Medicines Agency (EMA) validation objectives and might be used in pediatric and adult PK studies. Full article
(This article belongs to the Special Issue Recent Advances in Drug Metabolism, Transport, and Pharmacokinetics)
►▼ Show Figures

Figure 1

Review

Jump to: Research

19 pages, 2289 KiB  
Review
CRRT Is More Than Just Continuous Renal Replacement Therapy
by Lóránd Erdélyi and Domonkos Trásy
Pharmaceuticals 2024, 17(12), 1571; https://doi.org/10.3390/ph17121571 - 22 Nov 2024
Viewed by 2447
Abstract
The physiology of the kidney has long been understood, and its mechanisms are well described. The pathology of renal failure is also a deeply researched area. It seems logical, therefore, to create devices that can replace the lost normal function of the kidney. [...] Read more.
The physiology of the kidney has long been understood, and its mechanisms are well described. The pathology of renal failure is also a deeply researched area. It seems logical, therefore, to create devices that can replace the lost normal function of the kidney. Using the physical processes that take place in the kidney, such as diffusion or convection across a membrane, various renal replacement therapies (RRT) have been created. There are those that are used intermittently and those that are used for longer periods. What they have in common is that all RRTs have the same purpose; to replace the excretory function of the kidney that has been lost. CRRT is an extracorporeal renal replacement therapy that effectively replicates the excretory function of the kidneys in cases of acute renal failure. However, it has become increasingly evident that this rapidly advancing treatment modality offers benefits beyond merely substituting kidney function, with its applications continuing to expand significantly with non-renal and other indications. The use of these devices has raised new questions, many of which are still not clearly answered. When should this start? Who should receive it? How long should it last? What indication should it be for? What modality should it be with? How does it change the pharmacokinetics of the medicines? To answer these questions, it is first worth understanding the mechanisms behind the processes and the factors that influence them. This should not only focus on the procedures used in RRT therapies, but also consider the patient’s condition and the physicochemical properties of the drugs. In this review, we aim to provide a literature summary to highlight the factors that may influence the success of RRT therapies. Full article
(This article belongs to the Special Issue Recent Advances in Drug Metabolism, Transport, and Pharmacokinetics)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop